Agenus is an immuno-oncology company designed to deliver innovation with speed for patients with cancer. We have a unique portfolio of antibodies, vaccines, cell therapies and adjuvants designed to treat cancers with optimal combinations.


In addition to our broad portfolio, we have an accomplished team of scientists, novel technology platforms and end-to-end capabilities from new target discovery to GMP manufacturing. We believe that combination therapies and a deep understanding of each patient’s cancer will be key drivers of success in substantially expanding the patient population benefiting from current immuno-oncology therapies. At Agenus, we believe we have assembled the capabilities to bring curative treatments to patients.

STO Details

  • Pre-sale start date TBA
  • Pre-sale end date TBA
  • Pre-sale token supply
Token Sale
  • STO start date Feb 19, 2019
  • STO end date Apr 30, 2019
  • STO token supply 100,000,000
  • Soft cap TBA
  • Hard cap size $100,000,000
Token details
  • Ticker BEST
  • Type ERC20
  • Additional Token Emission No
  • Accepted Currencies USD
  • Token distribution Smart Contract
  • Country Limitations
  • Registration Country United States
  • Registration Year 2013
Rating Review and Analytics
  • Investment Rating
  • Traction Low
  • Risk Score
Agenus Contacts
Ended 1849 days before $100,000,000
  • Start STO Feb 19, 2019
  • End STO Apr 30, 2019
  • Funding type
  • Token BEST
  • Price
  • Minimum investment
  • Product Type Digital Asset
  • KYC Yes
  • Whitepaper View

STOs that might interest you

View All →

  • Status Ended 1699 days before
  • Traction Low
  • Risk Score
  • Registration Year
  • Status Ended 1543 days before
  • Traction Low
  • Risk Score
  • Registration Year 2019
  • Status Ended 1803 days before
  • Traction Low
  • Risk Score
  • Registration Year 2017

Be the First to Get New Ratings